"There are only a handful of people in the world who have experience in running a direct-to-consumer genetic testing company — and I am one of them," Anne Wojcicki said.

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction. Last month,